CEO Corner

CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and challenges that biopharma CEOs and presidents can relate to and should be aware of.  

  • Building A Biotech with A Diversity Mindset
    Building A Biotech with A Diversity Mindset

    A diverse workplace is critical to building a successful biotech company. When you’re leading an organization working to bring life-saving drugs to the market, every second matters, and you need to attract and retain the best talent to be successful.

  • Leaders In Biotech: Raising Our Voices Beyond Industry’s Walls
    Leaders In Biotech: Raising Our Voices Beyond Industry’s Walls

    The CEO of Ovid Therapeutics, Jeremy Levin, feels no time has ever been better for biopharma leaders to speak out as part of their commitment to this industry.

  • What Drug Developers Can Learn From Silicon Valley
    What Drug Developers Can Learn From Silicon Valley

    Though biotechnology may never be as fast and efficient as software, we can make innovation and development faster — through nothing more than a Silicon-Valley way of thinking.

  • The Emergence Of New Gene Therapy Hubs
    The Emergence Of New Gene Therapy Hubs

    With gene therapy, we are at the dawn of another era of potentially rapid growth in the sector. And companies planning for their futures will once again consider a range of factors in identifying the optimal locations for gene therapy research and production centers.

  • How Moving Up Through The Ranks Can Shape A Biotech CEO
    How Moving Up Through The Ranks Can Shape A Biotech CEO

    All CEOs of small, publicly traded biotechs are required to wear many hats in the office every day. That’s why having a leader with a diverse background and experience in a variety of functional areas is an asset. Here we look at some of the various areas of expertise that can help create a more diverse C-suite executive.

  • Successfully Transforming An Organization: An Active Approach
    Successfully Transforming An Organization: An Active Approach

    Rich Daly, Chairman & CEO of Neuralstem, Inc., pens this month column and gives some enlightening anecdotes about what it takes to make "transformational" changes at a biopharma company.

  • Collaborating To Stem The Tide Of Emerging Antimicrobial Resistance
    Collaborating To Stem The Tide Of Emerging Antimicrobial Resistance

    Jeffrey Stein, Ph.D., president and CEO of Cidara Therapeutics, discusses what needs to be done now by drug companies and healthcare providers alike to stem the tide of emerging antimicrobial resistance, including collaboration to address market barriers.

  • The Biotech CEO — It’s Not For Everyone
    The Biotech CEO — It’s Not For Everyone

    I’ve often described the challenge of developing new medicines as analogous to the difficulty of climbing the highest mountains on Earth. If one follows that analogy, then seeking to develop a new treatment for Alzheimer’s disease is like climbing K2, the second highest peak — in winter.

  • The Case For A Healthcare Futures Market
    The Case For A Healthcare Futures Market

    Now is the time to develop a novel financial instrument which will provide risk transfer, transparency, and more certainty. A futures market in healthcare is a product whose time has come.

  • Understanding The Many Faces Of Innovation
    Understanding The Many Faces Of Innovation

    By its very definition, innovation may travel long and painful paths, require repeated failure, and invite numerous mistakes to gather experience for bringing forward something new. Lady luck also intervenes occasionally, as well.

More CEO Corner articles

BEYOND THE PRINTED PAGE

More From Beyond The Printed Page

LIFE SCIENCE LEADER BLOGS

More From Life Science Leader Blogs

@LIFESCILEADER1